RxDoctor Payments Data

Sheila Lambdin, APRN

Nurse Practitioner · Williamsburg, KYNPI 1093717233

Payments from drug & device makers

$1,013in general payments, 2019–2025

Across 54 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$172
  • Novo Nordisk$113
  • Vanda Pharmaceuticals Inc.$112
  • Bayer$102
  • Exact Sciences$95
  • Lilly USA, LLC$75
  • plus $345 from 10 others

What the payments were for

  • Food & beverage$96896%
  • Education$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,013 in reported general payments places this provider in the 65th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$206
Medicare patients
20
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$75,197
MounjaroTirzepatide69$73,364
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$46,723
EliquisApixaban41$30,952
FarxigaDapagliflozin Propanediol41$27,616
RybelsusSemaglutide15$25,994
TrulicityDulaglutide16$14,772
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$10,594
Lantus SolostarInsulin Glargine,hum.Rec.Anlog81$8,043
Breo ElliptaFluticasone/Vilanterol20$7,996
EntrestoSacubitril/Valsartan11$7,537
JanuviaSitagliptin Phosphate11$5,857
TrintellixVortioxetine Hydrobromide12$5,778
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,773
Combivent RespimatIpratropium/Albuterol Sulfate12$5,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$113$101,19187 claims
Lilly USA, LLCMounjaro, Trulicity$75$88,13785 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$22$65,313102 claims
AstraZenecaFarxiga, Symbicort$172$33,22666 claims
AbbVieSynthroid$50$1,94740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Williamsburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →